Schnieders Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.8M Buy
10,691
+2,212
+26% +$2.26M 1.68% 14
2026
Q1
$7.8M Buy
8,479
+36
+0.4% +$36.5K 1.24% 20
2025
Q4
$9.07M Buy
8,443
+12
+0.1% +$11.5K 1.41% 17
2025
Q3
$6.43M Buy
8,431
+438
+5% +$326K 1.15% 22
2025
Q2
$6.23M Buy
7,993
+1,141
+17% +$887K 1.09% 25
2025
Q1
$5.66M Sell
6,852
-667
-9% -$555K 1.21% 24
2024
Q4
$5.8M Buy
7,519
+59
+0.8% +$48.9K 1.15% 22
2024
Q3
$6.61M Buy
7,460
+281
+4% +$253K 1.26% 21
2024
Q2
$6.5M Buy
7,179
+172
+2% +$138K 1.31% 22
2024
Q1
$5.45M Buy
7,007
+783
+13% +$557K 1.12% 26
2023
Q4
$3.63M Buy
6,224
+342
+6% +$200K 0.8% 32
2023
Q3
$3.16M Buy
5,882
+2,698
+85% +$1.39M 0.71% 38
2023
Q2
$1.49M Buy
3,184
+25
+0.8% +$10.5K 0.31% 62
2023
Q1
$1.08M Buy
3,159
+50
+2% +$16.9K 0.24% 77
2022
Q4
$1.14M Hold
3,109
0.26% 75
2022
Q3
$1M Buy
3,109
+2,409
+344% +$763K 0.27% 77
2022
Q2
$227K Hold
700
0.07% 167
2022
Q1
$200K Sell
700
-85
-11% -$21.9K 0.05% 196
2021
Q4
$217K Buy
+785
New +$199K 0.05% 193

Other funds holding LLY

Schnieders Capital Management's LLY Position: Q2 2026 in Review

Schnieders Capital Management increased its Eli Lilly (LLY) stake by 26% in Q2 2026, buying an estimated $2.26M and bringing the position to 10,691 shares worth $12.8M. The position accounts for 1.68% of the portfolio, ranked #14.

Schnieders Capital Management first reported a position in LLY in Q4 2021 and has held it in 19 quarters since. 1,587 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Schnieders Capital Management held 10,691 shares of Eli Lilly worth $12.8M as of Q2 2026.
  • Schnieders Capital Management bought 2,212 Eli Lilly shares in Q2 2026, an estimated $2.26M.
  • Eli Lilly made up 1.68% of Schnieders Capital Management's portfolio in Q2 2026, its #14 holding.
  • Schnieders Capital Management first reported a position in Eli Lilly in Q4 2021 and has held it in 19 quarters since.
  • 1,587 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Schnieders Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.